Back to Agenda
Session 3: OPDP Research Update (Recorded)
Session Chair(s)
Kathryn Aikin, PhD, MS
Senior Social Science Analyst, Research Team Lead, OPDP, CDER
FDA, United States
Individual FDA/OPDP researchers will present findings from OPDP research studies. Attendees will gain a better understanding of the FDA/OPDP Research program and how it may contribute to knowledge, guidance, and policy development. This session is designed to educate attendees on the regulatory research FDA has done to help inform policy and guidance development.
Learning Objective : At the conclusion of this session, participants should be able to:- Understand the holistic research agenda of FDA/OPDP
- Provide the audience with a view into individual topic areas and how they fit together
- Identify insight into results of recent research
Speaker(s)
Introduction to the OPDP Research Program
Kathryn Aikin, PhD, MS
FDA, United States
Senior Social Science Analyst, Research Team Lead, OPDP, CDER
Animation in Direct-to-Consumer Prescription Drug Television Advertising
Amie O'Donoghue, PhD
FDA, United States
Social Science Analyst, OPDP, OMP, CDER
Physician and Consumer Capability to Detect and Inclination to Report Deceptive Prescription Drug Promotion
Kevin R. Betts, PhD
FDA, United States
Social Science Analyst, OPDP, OMP, CDER
Consumers’ Understanding of Oncology Clinical Endpoints: Focus Group Findings
Helen W. Sullivan, PhD, MPH
FDA, United States
Social Science Analyst, OPDP, OMP, CDER
Consumers’ Experience with and Attitudes Toward Direct-to-Consumer Prescription Drug Promotion: A Nationally Representative Survey - Selected Findings
Kathryn Aikin, PhD, MS
FDA, United States
Senior Social Science Analyst, Research Team Lead, OPDP, CDER
Have an account?